Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose dexamethasone plus NEPA for CCRT-induced CINV after radical cervical cancer surgery
ChiCTR2500106187Phase 4Not yet recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of netupitant + palonosetron and dexamethasone in Cervical Cancer (CC), chemotherapy-induced nausea and vomiting (CINV) and post-radiation nausea and vomiting (RINV) (3 arms), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoints: Complete remission during overall risk period, Complete remission in acute and delayed phases and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
netupitant + palonosetrondexamethasone
03
Conditions
Cervical Cancer (CC)chemotherapy-induced nausea and vomiting (CINV)post-radiation nausea and vomiting (RINV)
Beyond the preview
Go deeper on ChiCTR2500106187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106187.